Last updated 54 days ago

Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio

748 patients around the world
Available in Argentina
The study will consist of a screening period, a treatment and assessment period and an End of Study visit. Eligibility for the study will be determined during a screening period. Subjects who meet the eligibility criteria will be randomised to either AVT16 or Entyvio.
Alvotech Swiss AG
1Research sites
748Patients around the world

This study is for people with

Ulcerative colitis
Moderate/severe ulcerative colitis

Requirements for the patient

To 80 Years
All Gender

Medical requirements

Capable of giving signed informed consent.
Male and female subjects from 18 to 80 years of age.
Diagnosis of Ulcerative Colitis.
Diagnosis of Crohn's colitis.
Extensive colonic resection.
Active or latent tuberculosis.

Sites

Centro de Investigaciones Médicas Tucumán
Recruiting
Lavalle 506, T4000 San Miguel de Tucumán, Tucumán, Argentina
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy